EFSA flags health concerns over hydroxyanthracene in food

By Katy Askew contact

- Last updated on GMT

No 'safe limit' for consumption of hydroxyanthracene - EFSA ©iStock/AnnaIvanova
No 'safe limit' for consumption of hydroxyanthracene - EFSA ©iStock/AnnaIvanova

Related tags: Nutrition, Food, European food safety authority

The European Food Safety Authority (EFSA) has confirmed it has “health concerns” over the use of hydroxyanthracene derivatives in food.

The European food safety watchdog warned that “some substances”​ belonging to the group of plant-based ingredients known as hydroxyanthracene derivatives “can damage DNA”​ and “may cause cancer”​ when added to food.

The EFSA concluded that certain hydroxyanthracene derivatives are genotoxic and said it is therefore not possible to set a “safe”​ daily intake. When tested in animal studies, some of these substances have also been shown to cause cancer in the intestine, the EFSA added.

This group of substances naturally occurs in plants such as aloe or senna species.

Health claim stands

An EFSA spokesperson stressed that the safety body warns against the prolonged use, or high levels of consumption, of foods containing hydroxyanthracene derivatives. However, the spokesperson also told FoodNavigator that the EFSA has approved a health claim for hydroxyanthracene derivatives. The EFSA found that hydroxyanthracene derivatives in food can improve bowel function.

“In 2013, EFSA substantiated a health claim related to hydroxyanthracene derivatives in food and improvement of bowel function, but advised against the long-term use and high doses due to potential safety concerns,”​ the spokesperson explained.

At the time, the EFSA’s Dietetic Products, Nutrition and Allergies (NDA) Panel noted: “stimulant laxatives should not be consumed continually for periods longer than one to two weeks”​ and “the use of stimulant laxatives for more than two weeks requires medical supervision”.

The European Commission subsequently asked EFSA to assess the safety of these plant ingredients when used in foods, and provide advice on a daily intake not associated with adverse health effects.

The EFSA’s latest assessment that it is impossible to set "safe"​ limits will now be passed to regulators, the spokesperson added. “In terms of next steps, EFSA’s advice will feed into discussions among the regulators – [the] European Commission and ​EU Member States.”

Green light for medicinal use

The medicinal use of hydroxyanthracene derivatives for the treatment of constipation remains approved by the European Medicines Agency.

According to EMA recommendations, the dose of hydroxyanthracene derivatives used in herbal medicinal laxative products should not exceed 30 mg per day for a maximum period of two weeks. Use is approved in in adults only and consumption is not recommended for pregnant and lactating women as well as in children.

Related news

Show more

Related products

show more

Plant-based alternatives to thrill your tastebuds

Plant-based alternatives to thrill your tastebuds

Tereos Starch & Sweeteners Europe | 25-May-2018 | Technical / White Paper

Tereos has launched a range of delicious, 100% plant-based solutions for the food industry. Sauté Végétal is the first example of this new range of high-protein...

Exploring Fibre Fermentation Profiles

Exploring Fibre Fermentation Profiles

Tate and Lyle | 27-Apr-2018 | Technical / White Paper

ProDigest developed the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®), which explores the fermentation profiles of fibres and evaluates...

Related suppliers

Follow us

Products

View more

Webinars